Fountain Healthcare Partners (“Fountain”) announced on 5/23/19 the initial closing of its third fund, Fountain Healthcare Partners Fund III, L.P. (“Fund III”) with €118 million of committed... read more
Fountain Healthcare Partners (“Fountain”) announced on 5/23/19 the initial closing of its third fund, Fountain Healthcare Partners Fund III, L.P. (“Fund III”) with €118 million of committed... read more
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced on 5/22/19 the pricing of its underwritten public offering of 7,000,000 shares of its... read more
Sofinnova Partners, a European venture capital firm specializing in Life Sciences, announced today the launch of MD Start III, which closed above its original target of €40 million. With this new... read more
Guardant Health Filed for a public offering of up to 5,175,000 shares of common stock. At current prices this would raise $405 million+. Guardant trades on NASDAQ under the symbol, “GH.”
... read more
For an extended time, IBT has consulted with the US Food and Drug Administration (FDA) on how the company’s planned Phase III study should be designed. IBT announced on 5/19/19 that the FDA has... read more